Search research articles
Contact Us
Filters
Showing results (1-10 of 147) with videos related to
Page
of 15
Sort By:
The American Journal of Cardiology
|
June 14, 2008
The safety of niacin in the US Food and Drug Administration adverse event reporting database
Alawi A Alsheikh-Ali, Richard H Karas
Preventive Cardiology
|
April 30, 2005
Adverse events with concomitant amiodarone and statin therapy
Alawi A Alsheikh-Ali, Richard H Karas
Current Atherosclerosis Reports
|
February 21, 2009
The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials
Alawi A Alsheikh-Ali, Richard H Karas
BMJ (Clinical Research Ed.)
|
May 22, 2010
Balancing the intended and unintended effects of statins
Alawi A Alsheikh-Ali, Richard H Karas
Journal of Clinical Lipidology
|
February 5, 2011
Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing analysis
Alawi A Alsheikh-Ali, Richard H Karas
The American Journal of Cardiology
|
May 29, 2004
Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones
Alawi A Alsheikh-Ali, Richard H Karas
The American Journal of Cardiology
|
January 31, 2007
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)
Alawi A Alsheikh-Ali, Richard H Karas
Circulation. Cardiovascular Quality and Outcomes
|
December 25, 2009
Anticoagulation control in atrial fibrillation: optimizing risks and benefits
Alawi A Alsheikh-Ali, N A Mark Estes
Annals of Internal Medicine
|
December 22, 2010
Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk
Haseeb Jafri, Alawi A Alsheikh-Ali, Richard H Karas
The American Journal of Cardiology
|
December 26, 2007
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use
Noa Holoshitz, Alawi A Alsheikh-Ali, Richard H Karas
Page
of 15
Search research articles
Search
Showing results (1-10 of 147) with videos related to
Sort By:
Page
of 15
The American Journal of Cardiology
|
June 14, 2008
The safety of niacin in the US Food and Drug Administration adverse event reporting database
Alawi A Alsheikh-Ali, Richard H Karas
Preventive Cardiology
|
April 30, 2005
Adverse events with concomitant amiodarone and statin therapy
Alawi A Alsheikh-Ali, Richard H Karas
Current Atherosclerosis Reports
|
February 21, 2009
The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials
Alawi A Alsheikh-Ali, Richard H Karas
BMJ (Clinical Research Ed.)
|
May 22, 2010
Balancing the intended and unintended effects of statins
Alawi A Alsheikh-Ali, Richard H Karas
Journal of Clinical Lipidology
|
February 5, 2011
Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing analysis
Alawi A Alsheikh-Ali, Richard H Karas
The American Journal of Cardiology
|
May 29, 2004
Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones
Alawi A Alsheikh-Ali, Richard H Karas
The American Journal of Cardiology
|
January 31, 2007
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)
Alawi A Alsheikh-Ali, Richard H Karas
Circulation. Cardiovascular Quality and Outcomes
|
December 25, 2009
Anticoagulation control in atrial fibrillation: optimizing risks and benefits
Alawi A Alsheikh-Ali, N A Mark Estes
Annals of Internal Medicine
|
December 22, 2010
Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk
Haseeb Jafri, Alawi A Alsheikh-Ali, Richard H Karas
The American Journal of Cardiology
|
December 26, 2007
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use
Noa Holoshitz, Alawi A Alsheikh-Ali, Richard H Karas
Page
of 15